Implantation of Valves in Veins

Health care, Life sciences

UNMET NEED

Mitral insufficiency is characterized by partial closure or non-closure of the mitral valve. This dysfunction leads to mitral regurgitation, with blood flowing back through the valve into the heart’s left atrium. Left untreated, mitral insufficiency results in pulmonary edema or cardiogenic shock, which can lead to the patient’s death. There are many treatment options and prostheses on the market, but 50% of the patients are not eligible for an open-heart surgery and percutaneous surgery is limited by the anatomical geometry of the valve to be replaced.

Even if the cardiac valve market is in growth (2 billion USD with a CAGR of 20%), 250 000 people have no options for mitral valve replacement in North America.

SOLUTION OVERVIEW

The solution is a personalized valve system and an innovative implantation system that includes a personalized and percutaneous valve prosthesis designed for an in-vein heterotopic implantation.

Value proposition

The prosthesis system reduces the consequences of severe mitral insufficiency without replacing the patient’s defective natural valve.
Percutaneous implantation of the prosthesis represents an interventional advantage for surgeons and patients, due to the less invasive nature of the operation.
The prosthesis is personalized that increase the eligibility for implantation.

Competitive advantages

The device enables non-eligible for open or percutaneous surgery, or who has already undergone a failed replacement operation, to have a chance of being treated and extending their life expectancy.

Minimally invasive
Personalized
Relatively low cost
High eligibility for the procedure

BUSINESS OPPORTUNITY

Technology available for in-licensing
Seeking an industrial partner or entrepreneur
Eligibility to government financing for industry/academic development program

MARKET APPLICATIONS

First indication – mitral valve insufficiency
Secondary indications – aortic valves and tricuspid valves

IP PROTECTION

Provisional patent application

CONTACTS

François Tournoux

PRINCIPAL INVESTIGATOR
Assistant Clinical Professor
Department of Medicine, Université de Montréal
CHUM Research Center

Gad Sabbatier

CONTACT
Project Manager, Science and Technology
C 418 650-2829 x 230
Gad.sabbatier@axelys.ca